Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real‐World Cohort of 77 Patients
CNS Neuroscience & Therapeutics · 2025-04 · 31 (4)
DOI: 10.1111/cns.70391 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 16.04.2025. Verfasst von Sijia Hao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Discipline Innovation and Development Plan of Tangdu Hospital-Major Program of Clinical Research, National Key Research and Development Program of China, Key R & D plan of Shaanxi Province.
Abstract (Originalsprache)
Aims
Efgartigimod, a first‐in‐class neonatal Fc receptor antagonist, is approved for generalized myasthenia gravis (gMG). Its safety and efficacy across MG subtypes remain unclear.
Methods
This single‐center real‐world study (September 2023–July 2024) analyzed patients from an MG registry study in China. The primary efficacy outcome is the mean MG‐ADL score changes from baseline at weeks 4, 8, and 12, analyzed via generalized estimating equations. Safety was assessed by adverse events.
Results
Among 77 patients (mean age 56.1 ± 15.2 years; 59.7% male), 76 completed at least one treatment cycle (20 completed 2 cycles; 1 completed 3 cycles). After efgartigimod treatment, MG‐ADL scores decreased significantly by week 4 (mean difference −6.4, 95% CI −7.2 to −5.6, p < 0.001), sustaining through week 12 (−6.9, −7.8 to −6.1, p < 0.001). After the second cycle, MG‐ADL scores at week 12 trended lower than the first cycle (mean difference: −0.8, 95% CI: −2.0 to −0.5, p = 0.061). Efficacy was consistent across MGFA classes and thymoma status. In refractory patients, efgartigimod reduced MG‐ADL scores ( p < 0.001). Adverse events occurred in 3.9% (3/77).
Conclusion
Efgartigimod safely improved MG‐ADL scores and reduced steroid use across MG subtypes, with sustained efficacy through multiple treatment cycles. These findings support its potential when conventional therapies fail.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
ORCID-Profile: Sijia Hao, Huanhuan Li, Ting Chang
Förderung
- the Discipline Innovation and Development Plan of Tangdu Hospital-Major Program of Clinical Research
- National Key Research and Development Program of China
- Key R & D plan of Shaanxi Province
- National Natural Science Foundation of China
Zitieren
APA
Hao, S., Ruan, Z., Guo, R., Wang, Q., Huang, X., Sun, C., Li, H., Gao, T., Tang, Y., Cao, X., Liu, Y., Li, Z., & Chang, T. (2025). Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real‐World Cohort of 77 Patients. CNS Neuroscience & Therapeutics, 31(4). https://doi.org/10.1111/cns.70391
Vancouver
Hao S, Ruan Z, Guo R, Wang Q, Huang X, Sun C, et al. Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real‐World Cohort of 77 Patients. CNS Neuroscience & Therapeutics. 2025;31(4). doi:10.1111/cns.70391
BibTeX
@article{Hao2025,
author = {Hao, Sijia and Ruan, Zhe and Guo, Rongjing and Wang, Qingqing and Huang, Xiaoxi and Sun, Chao and Li, Huanhuan and Gao, Ting and Tang, Yonglan and Cao, Xiangqi and Liu, Yu and Li, Zhuyi and Chang, Ting},
title = {Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real‐World Cohort of 77 Patients},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
volume = {31},
number = {4},
doi = {10.1111/cns.70391}
}
EUVIMED